Monograph
J07AH09 - Meningococcus B, Multicomponent Vaccine |
Propably not porphyrinogenic |
PNP |
Important Information
Risk for gastrointestinal adverse events in the form of nausea and vomiting motivates vigilance against insufficient intake of food, especially of carbohydrate.
Side effects
Common adverse reactions of the meningococcus B vaccine that can be confused with an acute porphyric attack are nausea and vomiting. These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
The active substances in the meningococcus B vaccine are proteins and membrane vesicles and with regards to its pharmacokinetics it has no conceivable porphyrinogenic effects.
Chemical description
The meningococcus B multicomponent vaccine consists of recombinant proteins and outer membrane vesicles from meningococcal serogroup B (Bai 2011).
Therapeutic characteristics
The meningococcus B multicomponent vaccine is indicated for active immunization of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.
It is administered as two intramuscular injections, given at least one or two months apart.
Metabolism and pharmacokinetics
The meningococcus B vaccine is not metabolized by the cytochrome P450 system.
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles.
Bai X, Findlow J, et al. Expert Opin Biol Ther. 2011 Jul;11(7):969-85. |
21615224 |
| * | Government bodies | |
| 2. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015)
|
|
| * | Summary of Product Characteristics | |
| 3. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Bexsero.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia© NAPOS 2024